Breast

 

Early Stage, Locally Advanced

  •  BERENICE:    A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.

     

Node Positive (1-3 nodes), HR pos, HER2-neg

  • SWOG S1007: Rx PONDER Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer 

 

Stage IV

 

  • CTSU E2108: Early Surgery or Sta​ndard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
  • SWOG 1222:  Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer 
  • E2112:  Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic

Neo-Adjuvant

  •  Alliance  A011106:  Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
  •  NSABP B52:   Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer


 

  • For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238.​​​​